Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction II

Overview

About this study

The purpose of this study is to determine if the AliveCor (AC) 12-Lead Smartphone ECG is an acceptable substitute for a standard 12-Lead ECG in the identification of ST-Elevation Myocardial Infarction (STEMI) and non-ST segment Elevation Myocardial Infarction (NSTEMI).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Male or female ≥ 18 years of age.
Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.

Exclusion Criteria:

Inability or refusal of the patient and/or the patient’s legally acceptable representative to provide written informed consent for any reason.
Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/20/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Gregory Barsness, M.D.	Open for enrollment	Contact information: Ischemic Heart Disease (IHD) (507) 284-4256

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Gregory Barsness, M.D.

Open for enrollment

Contact information:

Ischemic Heart Disease (IHD)

(507) 284-4256

More information

Publications

Publications are currently not available

Clinical Trials